Achieve Life Sciences (ACHV) Stock Price, News & Analysis

Company Overview

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc. is based in Vancouver, Canada.

Key Stats

• Today's Range: $2.86 to $3.10
• 50-Day Range: $2.07 to $3.84
• 52-Week Range: $1.84 to $5.31
• Volume: 1.54 million shs
• Average Volume: 704,745 shs
• Market Capitalization: $149.21 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $14.67
• Consensus Rating: Strong Buy

Achieve Life Sciences Stock Analysis - MarketRank™

Achieve Life Sciences scored higher than 42% of companies evaluated by MarketBeat, and ranked 678th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Strong Buy

Consensus Rating

Achieve Life Sciences has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Achieve Life Sciences has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Achieve Life Sciences are expected to grow in the coming year, from ($1.17) to ($1.16) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Achieve Life Sciences is -2.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Achieve Life Sciences is -2.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Achieve Life Sciences has a P/B Ratio of 3.56. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.29% of the float of Achieve Life Sciences has been sold short.

Short Interest Ratio / Days to Cover

Achieve Life Sciences has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Achieve Life Sciences has recently increased by 14.34%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Achieve Life Sciences does not currently pay a dividend.

Dividend Growth

Achieve Life Sciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

8.29% of the float of Achieve Life Sciences has been sold short.

Short Interest Ratio / Days to Cover

Achieve Life Sciences has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Achieve Life Sciences has recently increased by 14.34%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.8 / 5
• News Sentiment: 0.25

News Sentiment

Achieve Life Sciences has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Achieve Life Sciences this week, compared to 2 articles on an average week.

Search Interest

Only 5 people have searched for ACHV on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added Achieve Life Sciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Achieve Life Sciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.00% of the stock of Achieve Life Sciences is held by insiders.

Percentage Held by Institutions

Only 33.52% of the stock of Achieve Life Sciences is held by institutions.

ACHV Stock Analysis - Frequently Asked Questions

How have ACHV shares performed this year?

Achieve Life Sciences' stock was trading at $3.52 at the beginning of 2025. Since then, ACHV shares have decreased by 17.0% and is now trading at $2.92.

How were Achieve Life Sciences' earnings last quarter?

Achieve Life Sciences, Inc. (NASDAQ:ACHV) posted its quarterly earnings results on Thursday, August, 7th. The biopharmaceutical company reported ($0.37) EPS for the quarter, meeting the consensus estimate of ($0.37).
Read the conference call transcript.

When did Achieve Life Sciences' stock split?

Shares of Achieve Life Sciences reverse split on Friday, July 31st 2020.The 1-20 reverse split was announced on Thursday, July 30th 2020. The number of shares owned by shareholders was adjusted after the market closes on Thursday, July 30th 2020. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Who are Achieve Life Sciences' major shareholders?

Achieve Life Sciences' top institutional shareholders include Franklin Resources Inc. (12.85%), Simplify Asset Management Inc. (3.41%), Hudson Bay Capital Management LP (3.38%) and Hudson Bay Capital Management LP (2.30%). Insiders that own company stock include John Bencich and Mark K Oki.
View institutional ownership trends.

How do I buy shares of Achieve Life Sciences?

Shares of ACHV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Achieve Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Achieve Life Sciences investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Meta Platforms (META), Moderna (MRNA), Netflix (NFLX) and Visa (V).

Company Calendar

• Last Earnings: 8/07/2025
• Today: 8/22/2025
• Next Earnings (Estimated): 11/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ACHV
• CIK: 949858
• Web: achievelifesciences.com
• Phone: (604) 210-2217
• Fax: 425-686-1600
• Employees: 20
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Achieve Life Sciences: $14.67
• High Price Target: $20.00
• Low Price Target: $12.00
• Potential Upside/Downside: +402.3%
• Consensus Rating: Strong Buy
• Rating Score (0-4): 3.50
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.46)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$39.83 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -193.49%
• Return on Assets: -116.68%

Debt

• Debt-to-Equity Ratio: 0.21
• Current Ratio: 6.64
• Quick Ratio: 6.64

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.82 per share
• Price / Book: 3.56

Miscellaneous

• Outstanding Shares: 51,100,000
• Free Float: 49,572,000
• Market Cap: $149.21 million
• Optionable: Optionable
• Beta: 1.30